ARASENS , 2022 NCT02799602
darolutamide plus doxetaxel plus ADT (n=651) vs. docetaxel plus ADT (n=655)
randomized controlled trial
darolutamide, androgen-deprivation therapy, and docetaxel
androgen-deprivation therapy, and docetaxel
metastatic, hormone-sensitive prostate cancer
double-blind